CBP/p300-IN-19 structure
|
Common Name | CBP/p300-IN-19 | ||
---|---|---|---|---|
CAS Number | 2592638-13-4 | Molecular Weight | 477.55 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C30H27N3O3 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of CBP/p300-IN-19CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity[1]. |
Name | CBP/p300-IN-19 |
---|
Description | CBP/p300-IN-19 is a potent p300/CBP HAT inhibitor with IC50s of 1.4, 2.2, >100, >100 µM for p300-HAT, CBP-HAT, PCAF, Myst3, respectively. CBP/p300-IN-19 shows antitumor activity[1]. |
---|---|
Related Catalog | |
Target |
p300:1.4 μM (IC50) PCAF:2.2 μM (IC50) CBP:>100 μM (IC50) Myst3:>100 μM (IC50) |
In Vitro | CBP/p300-IN-19 (compound 29) shows antiproliferative activity with EC50s of 5.3, 8.5, 6.2, 4.4, 1.2, 4.3, 3.6, 8.7, 6.4 µM for MCF-7, MDA-MB231, LNCaP, PC-3, PANC-1, MDA-PANC-28, Molm-13, MV4;11, RPMI-8226 cells, respectively[1]. CBP/p300-IN-19 (0, 5, 10 µM; 12 h) dose-dependenly inhibits the acetylation of H3K18, H3K9 and K27[1]. Western Blot Analysis[1] Cell Line: Kasumi-1 leukemia cells Concentration: 0, 5, 10 µM Incubation Time: 12 h Result: Dose-dependently inhibited the acetylation of H3K18, H3K9 and K27. |
References |
Molecular Formula | C30H27N3O3 |
---|---|
Molecular Weight | 477.55 |